Monopar Therapeutics Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 5 - Stock Incentive Plan (Tables)

Note 5 - Stock Incentive Plan (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

		*Options Outstanding*
		*Number of Shares Subject to Options*				*Weighted-Average Exercise Price*
Balance at January 1, 2022			1,543,989			$	4.78
Granted			604,064				2.83
Forfeited			(337,103	)			6.13
Exercised			(168,000	)			0.001
Balance at December 31, 2022			1,642,950				4.28
Granted⁽¹⁾			508,902				3.14
Forfeited⁽²⁾			(42,851	)			3.93
Exercised			—				—
Balance at December 31, 2023			2,109,001				4.01
Unvested options outstanding expected to vest⁽³⁾			601,746				3.37

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Exercise Prices		Number of Shares Subject to Options Outstanding				Weighted-Average Remaining Contractual Term in Years				Number of Shares Subject to Options Fully Vested and Exercisable				Weighted-Average Remaining Contractual Term in Years
$0.001 - $5.00			1,371,895				6.95				832,423				5.80
$5.01 - $10.00			617,942				5.50				555,668				5.30
$10.01 - $15.00			113,039				6.09				113,039				6.09
$15.01 - $20.00			6,125				6.09				6,125				6.09
			2,109,001				6.48				1,507,255				5.64

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

		*Restricted Stock Units*				*Weighted-Average Grant Date Fair Value per Unit*
Unvested balance at December 31, 2021			111,462			$	8.44
Granted			403,522				2.80
Vested			(149,706	)			4.07
Forfeited			(92,628	)			4.01
Unvested balance at December 31, 2022			272,650				4.00
Granted			368,345				3.16
Vested			(222,904	)			3.73
Forfeited			—				—
Unvested Balance at December 31, 2023			418,091				3.40

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

		*Years Ended December 31,*
		*2023*				*2022*

Stock options granted			508,902				604,064
Fair value of shares vested		$	980,455			$	970,451